Chinook Therapeutics, Inc. Peer Comparison

Metric Value Ranking
Market Cap $2.7 Billion 9/18 PCVX
$13.9B		 CERE
$8.2B		 ASND
$7.8B		 RVMD
$7.7B		 NUVL
$7.2B		 RNA
$5.5B		 CRNX
$4.3B		 ACLX
$4.1B		 KDNY
$2.7B		 SWTX
$2.4B		 DICE
$2.3B		 VRDN
$1.9B		 KURA
$1.4B		 DAWN
$1.2B		 TVTX
$1.1B		 PLRX
$663.3M		 THRX
$181.7M		 VTYX
$149.1M
Gross Margin 57% 8/18 VRDN
100%		 ACLX
95%		 SWTX
94%		 ASND
92%		 DAWN
91%		 TVTX
77%		 RNA
66%		 KDNY
57%		 KURA
0%		 RVMD
0%		 PLRX
0%		 PCVX
0%		 CERE
0%		 NUVL
0%		 DICE
0%		 THRX
0%		 VTYX
0%		 CRNX
-89%
Profit Margin -100% 13/18 KURA
0%		 RVMD
0%		 PLRX
0%		 PCVX
0%		 CERE
0%		 NUVL
0%		 DICE
0%		 THRX
0%		 VTYX
0%		 DAWN
-54%		 SWTX
-67%		 ACLX
-99%		 KDNY
-100%		 ASND
-100%		 CRNX
-100%		 RNA
-100%		 VRDN
-100%		 TVTX
-100%
EBITDA margin -6934% 16/18 ASND
-49%		 SWTX
-74%		 KURA
-100%		 RVMD
-100%		 PLRX
-100%		 PCVX
-100%		 CERE
-100%		 NUVL
-100%		 DICE
-100%		 THRX
-100%		 VTYX
-100%		 TVTX
-105%		 ACLX
-123%		 DAWN
-1396%		 RNA
-4007%		 KDNY
-6934%		 CRNX
-20659%		 VRDN
-83719%
Quarterly Revenue $1.0 Million 7/18 ASND
$105.4M		 SWTX
$59.7M		 TVTX
$54.1M		 ACLX
$27.4M		 DAWN
$8.2M		 RNA
$2.0M		 KDNY
$1.0M		 CRNX
$399,000		 VRDN
$72,000		 KURA
$0		 RVMD
$0		 PLRX
$0		 PCVX
$0		 CERE
$0		 NUVL
$0		 DICE
$0		 THRX
$0		 VTYX
$0
Quarterly Earnings -$66.9 Million 11/18 DAWN
-$4.4M 		THRX
-$13.5M 		ACLX
-$27.2M 		VTYX
-$32.0M 		DICE
-$34.8M 		SWTX
-$39.9M 		KURA
-$50.8M 		PLRX
-$55.9M 		NUVL
-$57.2M 		VRDN
-$65.0M 		KDNY
-$66.9M 		TVTX
-$70.4M 		RNA
-$70.8M 		CRNX
-$74.1M 		PCVX
-$128.7M 		CERE
-$131.9M 		RVMD
-$133.2M 		ASND
-$144.0M
Quarterly Free Cash Flow -$61.8 Million 12/18 THRX
$3.0M 		VRDN
-$0 		VTYX
-$24.6M 		DICE
-$30.4M 		ACLX
-$39.5M 		NUVL
-$41.2M 		KURA
-$42.5M 		PLRX
-$46.5M 		CRNX
-$46.6M 		TVTX
-$52.2M 		SWTX
-$54.0M 		KDNY
-$61.8M 		RNA
-$65.5M 		DAWN
-$66.3M 		ASND
-$111.8M 		CERE
-$119.9M 		RVMD
-$130.6M 		PCVX
-$166.8M
Trailing 4 Quarters Revenue $3.3 Million 9/18 ASND
$361.6M		 TVTX
$177.6M		 ACLX
$144.7M		 SWTX
$91.8M		 RNA
$10.6M		 DAWN
$8.8M		 PLRX
$4.8M		 RVMD
$4.6M		 KDNY
$3.3M		 CRNX
$1.4M		 KURA
$1.3M		 VRDN
$288,000		 PCVX
$0		 CERE
$0		 NUVL
$0		 DICE
$0		 THRX
$0		 VTYX
$0
Trailing 4 Quarters Earnings -$244.9 Million 11/18 ASND
$105.4M 		SWTX
$59.7M 		TVTX
$54.1M 		ACLX
$27.4M 		DAWN
$8.2M 		RNA
$2.0M 		KDNY
$1.0M 		CRNX
$399,000 		VRDN
$72,000 		KURA
-$0 		RVMD
-$0 		PLRX
-$0 		PCVX
-$0 		CERE
-$0 		NUVL
-$0 		DICE
-$0 		THRX
-$0 		VTYX
-$0
Quarterly Earnings Growth -78% 15/18 DAWN
90% 		SWTX
49% 		VTYX
40% 		TVTX
18% 		THRX
8% 		ACLX
-14% 		ASND
-18% 		VRDN
-18% 		CERE
-26% 		PLRX
-36% 		KURA
-37% 		CRNX
-45% 		RNA
-51% 		DICE
-62% 		KDNY
-78% 		PCVX
-88% 		NUVL
-97% 		RVMD
-128%
Annual Earnings Growth -85% 15/18 TVTX
58% 		ACLX
49% 		ASND
32% 		VTYX
22% 		VRDN
12% 		SWTX
-6% 		THRX
-12% 		DAWN
-15% 		CERE
-20% 		DICE
-26% 		RNA
-34% 		CRNX
-41% 		KURA
-42% 		PLRX
-55% 		KDNY
-85% 		NUVL
-94% 		RVMD
-127% 		PCVX
-133%
Quarterly Revenue Growth 0% 4/18 SWTX
925% 		ASND
185% 		ACLX
91% 		KDNY
0% 		KURA
0% 		PCVX
0% 		CERE
0% 		VRDN
0% 		NUVL
0% 		DAWN
0% 		DICE
0% 		THRX
0% 		VTYX
0% 		TVTX
-9% 		RNA
-12% 		CRNX
-60% 		RVMD
-100% 		PLRX
-100%
Annual Revenue Growth 0% 6/18 SWTX
308% 		ASND
222% 		ACLX
113% 		RNA
18% 		PLRX
14% 		KDNY
0% 		KURA
0% 		PCVX
0% 		CERE
0% 		NUVL
0% 		DAWN
0% 		DICE
0% 		THRX
0% 		VTYX
0% 		VRDN
-21% 		TVTX
-23% 		CRNX
-85% 		RVMD
-91%
Cash On Hand $127.1 Million 8/18 RNA
$575.8M 		PCVX
$518.7M 		ASND
$351.9M 		CERE
$320.4M 		CRNX
$302.2M 		RVMD
$275.7M 		DAWN
$239.6M 		KDNY
$127.1M 		VRDN
$107.7M 		ACLX
$100.2M 		PLRX
$80.4M 		SWTX
$79.9M 		NUVL
$77.7M 		DICE
$73.5M 		THRX
$46.9M 		KURA
$45.2M 		VTYX
$40.9M 		TVTX
$32.3M
Short Term Debt $4.3 Million 7/18 ASND
$482.8M 		ACLX
$26.4M 		RVMD
$8.3M 		CRNX
$7.4M 		PCVX
$7.3M 		TVTX
$5.2M 		KDNY
$4.3M 		RNA
$3.8M 		CERE
$3.5M 		VRDN
$3.0M 		KURA
$2.3M 		DICE
$1.5M 		VTYX
$971,000 		SWTX
$958,000 		THRX
$759,000 		DAWN
$190,000 		PLRX
$98,000 		NUVL
-$0
Long Term Debt $29.7 Million 8/18 TVTX
$378.1M		 CERE
$364.8M		 ASND
$252.3M		 RVMD
$79.1M		 ACLX
$47.9M		 CRNX
$45.9M		 PLRX
$30.1M		 KDNY
$29.7M		 PCVX
$18.3M		 VRDN
$17.5M		 DICE
$11.0M		 VTYX
$10.3M		 KURA
$8.6M		 SWTX
$6.1M		 RNA
$4.6M		 THRX
$2.9M		 NUVL
$0		 DAWN
$0
PE -1.00 1/18 KDNY
-1.00		 KURA
-1.00		 ASND
-1.00		 CRNX
-1.00		 RVMD
-1.00		 SWTX
-1.00		 PLRX
-1.00		 PCVX
-1.00		 RNA
-1.00		 CERE
-1.00		 VRDN
-1.00		 TVTX
-1.00		 NUVL
-1.00		 DAWN
-1.00		 DICE
-1.00		 THRX
-1.00		 ACLX
-1.00		 VTYX
-1.00
PS 808.88 5/18 VRDN
6429.32		 CRNX
3121.68		 RVMD
1682.10		 KURA
1116.33		 KDNY
808.88		 RNA
520.69		 PLRX
137.05		 DAWN
136.57		 ACLX
28.31		 SWTX
26.57		 ASND
19.73		 TVTX
5.97		 PCVX
-1.00		 CERE
-1.00		 NUVL
-1.00		 DICE
-1.00		 THRX
-1.00		 VTYX
-1.00
PB 7.58 5/18 TVTX
70.04		 CERE
14.51		 NUVL
11.35		 ACLX
8.41		 KDNY
7.58		 PCVX
7.01		 CRNX
5.20		 RVMD
4.74		 RNA
4.52		 SWTX
4.38		 DICE
4.37		 DAWN
3.90		 VRDN
3.50		 KURA
3.04		 PLRX
1.69		 THRX
0.81		 VTYX
0.53		 ASND
0.00
PC 21.30 11/18 NUVL
93.03		 ACLX
40.88		 TVTX
32.86		 KURA
31.38		 DICE
30.91		 SWTX
30.52		 RVMD
27.86		 PCVX
26.83		 CERE
25.56		 ASND
22.27		 KDNY
21.30		 VRDN
17.20		 CRNX
14.31		 RNA
9.59		 PLRX
8.25		 DAWN
4.99		 THRX
3.88		 VTYX
3.64
Liabilities to Equity 0.37 4/18 TVTX
35.38		 CERE
1.00		 ACLX
0.51		 KDNY
0.37		 DAWN
0.31		 PLRX
0.23		 CRNX
0.13		 RVMD
0.12		 KURA
0.11		 SWTX
0.11		 VRDN
0.11		 RNA
0.10		 VTYX
0.10		 NUVL
0.06		 DICE
0.06		 PCVX
0.05		 THRX
0.05		 ASND
0.00
ROA -0.50 17/18 ACLX
-7% 		DICE
-18% 		RNA
-19% 		PCVX
-24% 		THRX
-24% 		TVTX
-26% 		NUVL
-26% 		CRNX
-28% 		RVMD
-29% 		KURA
-36% 		VRDN
-39% 		PLRX
-40% 		VTYX
-40% 		CERE
-41% 		DAWN
-44% 		SWTX
-49% 		KDNY
-50% 		ASND
-69%
ROE -0.69 16/18 ASND
231% 		ACLX
-11% 		DICE
-19% 		RNA
-21% 		PCVX
-25% 		THRX
-25% 		NUVL
-27% 		CRNX
-31% 		RVMD
-32% 		KURA
-40% 		VRDN
-43% 		VTYX
-44% 		PLRX
-50% 		SWTX
-54% 		DAWN
-57% 		KDNY
-69% 		CERE
-82% 		TVTX
-963%
Current Ratio 3.71 14/18 THRX
23.22		 PCVX
20.64		 NUVL
17.68		 DICE
17.42		 VTYX
10.89		 RNA
10.66		 KURA
10.50		 VRDN
10.40		 SWTX
10.19		 RVMD
9.54		 CRNX
8.93		 PLRX
5.31		 DAWN
4.27		 KDNY
3.71		 ACLX
2.97		 CERE
2.00		 TVTX
1.03		 ASND
0.77
Quick Ratio 2.26 14/18 KDNY
-1.00		 KURA
-1.00		 ASND
-1.00		 CRNX
-1.00		 RVMD
-1.00		 SWTX
-1.00		 PLRX
-1.00		 PCVX
-1.00		 RNA
-1.00		 CERE
-1.00		 VRDN
-1.00		 TVTX
-1.00		 NUVL
-1.00		 DAWN
-1.00		 DICE
-1.00		 THRX
-1.00		 ACLX
-1.00		 VTYX
-1.00
Long Term Debt to Equity 0.08 4/18 TVTX}
24.96		 CERE}
0.65		 ACLX}
0.10		 KDNY}
0.08		 PLRX}
0.08		 CRNX}
0.06		 RVMD}
0.05		 VTYX}
0.04		 VRDN}
0.03		 KURA}
0.02		 DICE}
0.02		 SWTX}
0.01		 PCVX}
0.01		 THRX}
0.01		 RNA}
0.00		 NUVL}
0.00		 DAWN}
0.00		 ASND}
-0.96
Debt to Equity 0.10 5/18 TVTX
26.62		 CERE
0.65		 PLRX
0.15		 ACLX
0.15		 KDNY
0.10		 CRNX
0.06		 RVMD
0.05		 KURA
0.04		 VRDN
0.04		 VTYX
0.04		 DICE
0.02		 THRX
0.02		 SWTX
0.01		 PCVX
0.01		 RNA
0.01		 NUVL
0.00		 DAWN
0.00		 ASND
-2.81
Burn Rate 1.84 11/18 DAWN
53.79		 RNA
8.01		 PCVX
3.95		 CRNX
3.89		 THRX
3.40		 ACLX
2.81		 CERE
2.17		 DICE
2.06		 RVMD
1.99		 SWTX
1.98		 KDNY
1.84		 VRDN
1.62		 PLRX
1.41		 NUVL
1.36		 VTYX
1.26		 ASND
1.22		 KURA
0.87		 TVTX
0.37
Cash to Cap 0.05 8/18 VTYX
0.27		 THRX
0.26		 DAWN
0.20		 PLRX
0.12		 RNA
0.10		 CRNX
0.07		 VRDN
0.06		 KDNY
0.05		 ASND
0.04		 RVMD
0.04		 PCVX
0.04		 CERE
0.04		 KURA
0.03		 SWTX
0.03		 TVTX
0.03		 DICE
0.03		 ACLX
0.02		 NUVL
0.01
CCR 0.92 7/18 DAWN
15.03		 ACLX
1.45		 SWTX
1.35		 PCVX
1.30		 RVMD
0.98		 RNA
0.93		 KDNY
0.92		 CERE
0.91		 DICE
0.87		 KURA
0.84		 PLRX
0.83		 ASND
0.78		 VTYX
0.77		 TVTX
0.74		 NUVL
0.72		 CRNX
0.63		 VRDN
0.00		 THRX
-0.22
EV to EBITDA -37.41 12/18 PCVX}
-1.00		 CERE}
-1.00		 NUVL}
-1.00		 DICE}
-1.00		 THRX}
-1.00		 VTYX}
-1.00		 DAWN}
-8.36		 PLRX}
-10.72		 TVTX}
-25.25		 KURA}
-27.33		 VRDN}
-29.27		 KDNY}
-37.41		 RVMD}
-48.70		 CRNX}
-49.43		 SWTX}
-53.67		 RNA}
-60.43		 ACLX}
-120.63		 ASND}
-191.14
EV to Revenue 781.05 5/18 VRDN
6126.49		 CRNX
2942.01		 RVMD
1640.86		 KURA
1093.93		 KDNY
781.05		 RNA
467.15		 PLRX
132.89		 DAWN
109.22		 ACLX
28.13		 SWTX
25.78		 ASND
24.79		 TVTX
8.06		 PCVX
-1.00		 CERE
-1.00		 NUVL
-1.00		 DICE
-1.00		 THRX
-1.00		 VTYX
-1.00

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions